Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

U.S. Lawmaker Launches Investigation into Pharma Drug Pricing

Yasmeen Abutaleb  |  January 15, 2019

WASHINGTON (Reuters)—A top U.S. lawmaker has launched an investigation into pharmaceutical industry pricing practices, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Rep. Elijah Cummings (D-Md.), who chairs the U.S. House Oversight Committee, sent letters to 12 drug makers seeking information on price increases, investment in research…

Filed under:Drug Updates Tagged with:costsdrug costdrug cost legislationU.S. Congressional Budget Office

Former Insys CEO Pleads Guilty to Opioid Kickback Scheme

Nate Raymond  |  January 10, 2019

BOSTON (Reuters)—The former chief executive of Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a nationwide scheme to bribe doctors to prescribe an addictive opioid medication and has agreed to become a government witness. Michael Babich, who resigned as the Arizona-based drugmaker’s CEO in 2015, pleaded guilty in federal court in Boston to…

Filed under:Uncategorized Tagged with:guilty pleaInsys CEOInsys Therapeutics IncMichael Babichopioid crisisopioid kickback scheme

Cigna Closes $54 Billion Purchase of Express Scripts

Caroline Humer  |  December 29, 2018

NEW YORK (Reuters)—Cigna Corp on Thursday closed its $54-billion deal to buy Express Scripts Holding Co, creating one of the biggest providers of pharmacy benefits and insurance plans in the United States, a combination it says will help it improve healthcare coordination and cut costs. Cigna’s deal puts it in direct competition with two other…

Filed under:Uncategorized Tagged with:Cigna Corp.Express Scripts Holding Co

How Advances in Artificial Intelligence May Aid Rheumatology

Richard Quinn  |  December 19, 2018

From digital scribes to predictive pharmacology—as artificial intelligence advances, technology has a lot to offer medicine. What opportunities lie ahead for rheumatologists and their patients?

Filed under:Technology Tagged with:appsartificial intelligenceelectronic health record (EHR)Technology

The 2018 ARHP Merit Awards & ACR Distinguished Fellows

Carol Patton, with Keri Losavio  |  December 18, 2018

CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARHP Merit Awards about their individual contributions to advancing rheumatology. You’ll also find interviews…

Filed under:AwardsMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)Daniel SchafferDanielle RiceDr. Ann Marie SzymanskiDr. Antonia ValenzuelaDr. April M. JorgeDr. Bella MehtaDr. Brittany AdlerDr. Carol A. OatisDr. Charles G. HelmickDr. Christina H. OpavaDr. DeAnna A. Baker FrostDr. Debbie Ehrmann-FeldmanDr. Marcela A. FerradaDr. Patrick R. WoodDr. Sara AlehashemiDr. Shudan WangHiral MasterJanalee TaylorLisa Robbins

Tips for Using Digital Health Tools

Thomas R. Collins  |  December 18, 2018

CHICAGO—Approximately 200,000 health apps are available through major app stores. Some offer real benefits, said Brennan Spiegel, MD, MSHS, director of health services research at Cedars-Sinai Health System, Los Angeles, Calif. But most, he told attendees at the 2018 ACR/ARHP Annual Meeting, are “rubbish.” “They do one or two things only—and generally not well,” he…

Filed under:AppsMeeting ReportsTechnology Tagged with:2018 ACR/ARHP Annual Meetingmobile appsTechnologywearable device

Annual Meeting Speakers Review Studies Ranging from Opioids to Fibroblasts

Thomas R. Collins  |  December 18, 2018

CHICAGO—Findings on opioid efficacy, serum urate in osteoarthritis and arthrocentesis headlined the top research of the year discussed in the first half of a session at the 2018 ACR/ARHP Annual Meeting. The second half covered basic science findings, including summaries of new insights into the gender bias in autoimmune diseases, platelet microparticles in scleroderma and…

Filed under:Meeting ReportsResearch Rheum Tagged with:2018 ACR/ARHP Annual MeetingarthrocentesisfibroblastsGenderopioid efficacyOsteoarthritisRheumatoid Arthritis (RA)Scleroderma

Study Assesses the Role of Genetics & the Gut in Reactive Arthritis

Mary Beth Nierengarten  |  December 18, 2018

Genes may predispose people to have certain microbial signatures in their gut that, in turn, make them susceptible to developing reactive arthritis. This is the main finding of a recent study in which researchers investigated whether perturbations in the intestinal microbiome play a role in susceptibility to reactive arthritis in the face of triggers, such…

Filed under:ConditionsResearch Rheum Tagged with:Genesgut microbiotaReactive arthritis

ah_designs / shutterstock.com

The Perils of Pain Meds Revisited

Stephen G. Gelfand, MD, FACP, FACR  |  December 18, 2018

More than 10 years ago, I wrote a commentary in The Rheumatologist, called “Perils of Pain Meds,” about the over-prescribing of opioid analgesics for common causes of chronic noncancer pain, which was a major contributor to the opioid epidemic.1 Since that time, although there has been a greater than 20% decrease in opioid prescribing, the…

Filed under:Analgesics Tagged with:opioid crisis

psoriatic arthritis hand photo

New PsA Guideline Released

Kathy Holliman  |  December 17, 2018

The ACR & the National Psoriasis Foundation (NPF) have published a joint Guideline for the Treatment of Psoriatic Arthritis (PsA). The guideline will serve as an aid to practitioners managing active PsA in patients.

Filed under:Clinical Criteria/GuidelinesConditionsPsoriatic Arthritis Tagged with:first-line use of a TNFiJoint Guideline for the Treatment of Psoriatic Arthritis (PsA)National Psoriasis Foundation (NPF)oral small molecule (OSM) drugsPsA Resource CenterPsoriatic ArthritisTNFi biologic

  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 83
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences